TABLE 1.
Study subject characteristics.
| PD Pre-RT | PD Post-RT | % or point change | |
| Characteristics at baseline | |||
| Subjects (n) | 5 (4M, 1F) | ||
| Age (y) | 67 ± 2 | ||
| Time since diagnosis (y) | 5 ± 2 | ||
| Hoehn and Yahr stage | 2 (n = 3), | ||
| 3 (n = 2) | |||
| Levodopa equivalency dose | 455 ± 181 | ||
| Parkinson’s disease progression | |||
| MDS-UPDRS total score | 53 ± 7 | 47 ± 5 | −6 |
| Part I: Behavior/mentation/mood | 11 ± 4 | 9 ± 3 | −2 |
| Part II: ADL | 11 ± 3 | 11 ± 3 | 0 |
| Part III: motor | 29 ± 4 | 27 ± 4 | −2 |
| Part IV: dyskinesia | 2 ± 1 | 1 ± 1 | −1 |
| PDQ-39 total score | 38 ± 12 | 30 ± 11 | −8* |
| ADL subscore | 21 ± 3 | 12 ± 4 | −9* |
| Mobility subscore | 18 ± 8 | 17 ± 8 | −1 |
| Emotional well-being subscore | 31 ± 8 | 21 ± 10 | −10† |
| Cognitive impairment subscore | 34 ± 9 | 23 ± 8 | −11† |
| Myofiber CSA (μm2) | |||
| Type I | 4347 ± 342 | 5135 ± 399 | 21 ± 13 |
| Type IIa | 4532 ± 811 | 5582 ± 780 | 30 ± 15 |
| Type IIx/IIax** | 3762 ± 438 | – | – |
| Type II total | 3946 ± 514 | 5582 ± 780 | 42 ± 12* |
| Myofiber distribution (%) | |||
| Type I | 51 ± 4 | 46 ± 8 | 5 ± 6 |
| Type IIa | 34 ± 9 | 52 ± 8 | 18 ± 8† |
| Type IIx/IIax | 15 ± 6 | 2 ± 1 | −13 ± 5† |
| Neuromuscular function | |||
| Knee extension 1RM, kg | 77 ± 10 | 127 ± 14 | 67 ± 11* |
| Knee extension peak power, W | 234 ± 44 | 364 ± 42 | 67 ± 18* |
| Motor unit activation (%) | 0.68 ± 0.12 | 0.72 ± 0.16 | 5 ± 14 |
| Type I myofiber grouping | |||
| Mean group size | 241 ± 151 | 142 ± 72 | −18 ± 62 |
| Percent of I grouped | 57 ± 15 | 51 ± 18 | −6 ± 17 |
Values are mean ± SE. PD, Parkinson’s disease; RT, 16 weeks of high intensity resistance exercise rehab training; MDS-UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating Scale; PDQ-39, 39-item Parkinson’s Disease Questionnaire; ADL, activities of daily living; CSA, cross-sectional area; 1RM, one repetition maximum; W, watts. **Too few IIx/IIax fibers (i.e., ≤25) were present at post-RT time point to obtain a representative myofiber CSA. *P < 0.05 vs. pre-RT; †P < 0.10 vs. pre-RT. Data from the full study cohort are presented in a previous publication by our group (Kelly et al., 2014).